Interventions for Post-infectious Irritable Bowel Syndrome: a Systematic Review of Treatment Efficacy

Overview

Journal Trop Dis Travel Med Vaccines

Publisher Biomed Central

Specialty Infectious Diseases

Date 2017 Sep 9

PMID 28883933

Citations 2

Authors

Emma Torbicki

Justin Oh

Sharmistha Mishra

Andrea V Page

Andrea K Boggild

Affiliations

Soon will be listed here.

Abstract

Background: Post-infectious irritable bowel syndrome (PI-IBS) due to traveler's diarrhea is the second most common illness seen in post-travel clinics, yet its optimal management remains unknown. We performed a systematic review to evaluate treatment efficacy in PI-IBS.

Methods: We searched Medline, EMBASE, LILACS, CINAHL, CAB abstracts, and the Cochrane Library to February 3, 2014 for intervention studies of the pharmacologic and non-pharmacologic management of PI-IBS and examined the evidence according to a modified Grading of Recommendations Assessment, Development, and Evaluation (GRADE) scale.

Results: Of 336 records, 9 studies were included. Eight studies of pharmacologic interventions examined 5 agents (mesalazine or mesalamine, ondansetron, prednisolone, cholestyramine, and metronidazole). One study examined the non-pharmacologic intervention of different infant nutritional formulas following acute gastroenteritis. The quality of the evidence to date was low, with small sample size (fewer than 50 participants) and short duration of follow-up. Overall, the efficacy of pharmacological treatment ranged from no benefit (ondansetron and prednisolone) to moderately beneficial (cholestyramine and metronidazole). The evidence for mesalazine was equivocal: one study showed benefit, two others showed none.

Conclusions: Heterogeneity in outcome measures and low strength of evidence preclude recommendations on the optimal management of PI-IBS by a specific agent. More comparative intervention research into PI-IBS treatment is needed for consistent best practice in PI-IBS management. Clinicians may elect to pursue therapeutic trials of mesalazine, cholestyramine, or metronidazole in individual patients, but should be aware that data supporting the efficacy of these agents is limited.

Citing Articles

Post-Infectious Irritable Bowel Syndrome after an Epidemic of Gastroenteritis in South of Iran.

Sharifi M, Safarpour A, Barati-Boldaji R, Rahmati L, Karimi S, Bagheri Lankaran K Middle East J Dig Dis. 2023; 14(3):304-309.

PMID: 36619262 PMC: 9489434. DOI: 10.34172/mejdd.2022.287.

Rab5a Promotes Cytolethal Distending Toxin B-Induced Cytotoxicity and Inflammation.

Chen M, Chen Y, Fu R, Mao G, Liu S, Shen T Infect Immun. 2020; 88(10).

PMID: 32747601 PMC: 7504948. DOI: 10.1128/IAI.00132-20.

References

Lifshitz F, Fagundes-Neto U, Ferreira V, CORDANO A, Ribeiro H . The response to dietary treatment of patients with chronic post-infectious diarrhea and lactose intolerance. J Am Coll Nutr. 1990; 9(3):231-40. DOI: 10.1080/07315724.1990.10720374. View

Zboromyrska Y, Hurtado J, Salvador P, Alvarez-Martinez M, Valls M, Mas J . Aetiology of traveller's diarrhoea: evaluation of a multiplex PCR tool to detect different enteropathogens. Clin Microbiol Infect. 2014; 20(10):O753-9. DOI: 10.1111/1469-0691.12621. View

Tuteja A, Fang J, Al-Suqi M, Stoddard G, Hale D . Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study. Scand J Gastroenterol. 2012; 47(10):1159-64. DOI: 10.3109/00365521.2012.694903. View

Dizdar V, Gilja O, Hausken T . Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron. Neurogastroenterol Motil. 2007; 19(12):977-82. DOI: 10.1111/j.1365-2982.2007.00988.x. View

Connor B, Riddle M . Post-infectious sequelae of travelers' diarrhea. J Travel Med. 2013; 20(5):303-12. DOI: 10.1111/jtm.12049. View

Menon S, Jones B . Postinfective bile acid malabsorption: is this a long-term condition?. Eur J Gastroenterol Hepatol. 2011; 23(4):308-10. DOI: 10.1097/MEG.0b013e3283457ba6. View

Ilnyckyj A, Balachandra B, Elliott L, Choudhri S, Duerksen D . Post-traveler's diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol. 2003; 98(3):596-9. DOI: 10.1111/j.1572-0241.2003.07297.x. View

Barbara G, Cremon C, Pallotti F, De Giorgio R, Stanghellini V, Corinaldesi R . Postinfectious irritable bowel syndrome. J Pediatr Gastroenterol Nutr. 2009; 48 Suppl 2:S95-7. DOI: 10.1097/MPG.0b013e3181a15e2e. View

Boggild A, Geduld J, Libman M, Ward B, McCarthy A, Doyle P . Travel-acquired infections and illnesses in Canadians: surveillance report from CanTravNet surveillance data, 2009-2011. Open Med. 2014; 8(1):e20-32. PMC: 4085092. View

10.

Bhuiyan M, Majumder T, Raihan A, Roy P, Farha N, Kamal M . Histopathological alterations in post-infectious irritable bowel syndrome in Bangladeshi population. Mymensingh Med J. 2010; 19(2):275-81. View

11.

Niaz S, Sandrasegaran K, Renny F, Jones B . Postinfective diarrhoea and bile acid malabsorption. J R Coll Physicians Lond. 1997; 31(1):53-6. PMC: 5420841. View

12.

Hanevik K, Dizdar V, Langeland N, Eide G, Hausken T . Tolerability and effect of mesalazine in postinfectious irritable bowel syndrome. Aliment Pharmacol Ther. 2011; 34(2):259-60. DOI: 10.1111/j.1365-2036.2011.04715.x. View

13.

Ghoshal U, Ranjan P . Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol. 2011; 26 Suppl 3:94-101. DOI: 10.1111/j.1440-1746.2011.06643.x. View

14.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

15.

Ford A, Talley N, Spiegel B, Foxx-Orenstein A, Schiller L, Quigley E . Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008; 337:a2313. PMC: 2583392. DOI: 10.1136/bmj.a2313. View

16.

Bafutto M, de Almeida J, Leite N, Oliveira E, Gabriel-Neto S, Rezende-Filho J . Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. Arq Gastroenterol. 2011; 48(1):36-40. DOI: 10.1590/s0004-28032011000100008. View

17.

Spiller R, Campbell E . Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol. 2005; 22(1):13-7. DOI: 10.1097/01.mog.0000194792.36466.5c. View

18.

DuPont H . Gastrointestinal infections and the development of irritable bowel syndrome. Curr Opin Infect Dis. 2011; 24(5):503-8. DOI: 10.1097/QCO.0b013e32834a962d. View

19.

Dunlop S, Jenkins D, Neal K, Naesdal J, Borgaonker M, Collins S . Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2003; 18(1):77-84. DOI: 10.1046/j.1365-2036.2003.01640.x. View

20.

Stermer E, Lubezky A, Potasman I, Paster E, Lavy A . Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis. 2006; 43(7):898-901. DOI: 10.1086/507540. View